Haemonetics Stock Price, News & Analysis (NYSE:HAE)

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 6th 2018, which authorizes the company to repurchase $260,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its stock is undervalued.

Haemonetics Co. (NYSE:HAE) issued its earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.81 EPS for the quarter, topping the consensus estimate of $0.63 by $0.18. The medical instruments supplier had revenue of $238.50 million for the quarter, compared to the consensus estimate of $236.82 million. Haemonetics had a return on equity of 21.07% and a net margin of 5.05%. The company's quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 EPS. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for Haemonetics.

Haemonetics will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Haemonetics issued an update on its FY20 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $2.95-3.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.00 billion.

5 brokers have issued 12 month price targets for Haemonetics' shares. Their predictions range from $139.00 to $150.00. On average, they expect Haemonetics' share price to reach $144.40 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Haemonetics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

News stories about HAE stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Haemonetics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Haemonetics.

Haemonetics saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 826,400 shares, a decline of 13.5% from the August 30th total of 955,900 shares. Based on an average trading volume of 353,700 shares, the short-interest ratio is currently 2.3 days. Approximately 1.6% of the company's stock are short sold. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD) and Nevro (NVRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Micron Technology (MU), Adobe (ADBE), NVIDIA (NVDA), Aegean Marine Petroleum Network (ANW) and CA (CA).

Haemonetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.04%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), Zeke Capital Advisors LLC (0.01%), Crossmark Global Holdings Inc. (0.01%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers Inc. MA, Pacer Advisors Inc., First Citizens Bank & Trust Co., Zeke Capital Advisors LLC, Crossmark Global Holdings Inc. and Oakbrook Investments LLC. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Meeder Asset Management Inc., Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $127.25.

Haemonetics has a market capitalization of $6.46 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]